I know not who you speak of, as I only have one aka. I don't recall you mentioning how many akas you have though? And what is this agenda you speak of Loony Indian? BS is easily deciphered, unlike cryptographic keys.
Hmmn.. I did not know that Satoshi Nakamoto is a zionist. OTOH, the NSA is a different story...
PS: It only takes one aka to rule the universe
No real news out that I could see. Is it related to the 50/200 day SMA golden cross that just happened?
Oops.. meant 'get TO put large amounts of stock'. It's difficult to know what the net effect will be, but this is a fairly high number of contracts for this stock.
The stockholder who bought the puts can either sell them back before expiry or choose to put the stock to the put seller at the strike price. If the put buyer does not own the stock, the puts will get exercised and he will have a net short stock position.
I think the strongest card AMD has now is their microserver technology... Seamicro fabric with ARMH CPU's (64 bit will do the trick). They can only ever hope to dent INTC in the server market. There are too many other players in the CPU space for tablets/phones. But in the end any success will depend heavily on what the foundries can deliver.
I agree. but I suspect quantum-based keys. are the exception to this. Or do you think there's an agency smart enough to break quantum physics?
And in any case, a breakdown of BTC if it was to occur, would likely lead to rapid migration to an alternate cryptocurrency like LTC that does not rely on SHA2. It's NOT going to be easy to eradicate this technology. Heck, you probably think the NSA can crack quantum based keys too huh...
Well it's far from clear that the NSA inserted a back door into the algorithm. There is no hard evidence to suggest this.
I sold my shares in AMD a long time ago after they bought out graphics maker ATI, but I still like to follow the firm...
AMD has been capturing gaming console business for many cycles now. On the PC gaming front, it's been a battle back and forth with NVDA, but AMD is probably going to win this round with the R9. The problem for AMD is that on the CPU front, they have a formidable competitor in INTC. AMD no longer has fab capability and INTC has better process tehcnology than any foundrry.
AMD made a very interesting acquisition in Seamicro that positions them to capture a decent chunk of the fat developing microserver space. They have also moved to design ARMH-based CPUs that could fit nicely with the Seamicro business.
Is all this enough to go long? Hard to say. INTC has also been able to step all over AMD. And NVDA is also a solid competitor.
Was the UBS analyst wrong? Seems like yes. The Phase 3 results, while not ideal, still achieved some decent results. Thoughts anyone?
@@@@@It was observed in the trial that lifitegrast met the prespecified co-primary endpoint for the patient-reported symptom of eye dryness. The phase III development program of lifitegrast consists of three studies – OPUS-1, OPUS-2 and SONATA. After examining the total data from the complete clinical program, Shire expects to discuss the lifitegrast program with regulatory authorities. Lifitegrast was added to Shire’s pipeline following the acquisition of SARcode in Apr 2013.
Meanwhile, the acquisition of Premacure in Mar 2013 has also added a potential protein replacement therapy, premiplex, for the prevention of retinopathy of prematurity to Shire’s pipeline. Both these candidates strengthened Shire’s ophthalmology pipeline. We expect the acquisitions of SARcode and Premacure to develop a new business unit in ophthalmology for Shire.
@@@@@UBS analyst Guillaume van Renterghem downgraded Shire plc (NASDAQ:SHPG) from Buy to Neutral due to downside risk from upcoming clinical trials. Renterghem commented that the Lifitegrast Phase III trial for dry eye and Vyvanse in Major Depression Disorder could have "disappointing results" due to poor selection of patients. The analyst noted that 14 projects for dry eye have been unsuccessful over the past 10 years and believes the failure is due to identifying appropriate patients. UBS wrote that it is difficult to identify "patients with pure dry eye and excluding patients with dry eye like symptoms."
Further, the analyst noted the questionable validity of the Vyvanse patent. Shire had numerous patent challenges over the past five years and Vyvanse makes up approximately 35% of revenues. UBS analysis indicates strong historical trends of the depression drug.
Hmmm... there is a large open interest in near month puts... over 5000 Dec and 13000 January expiry contracts with strikes of 34 and higher. The holders are going to get put large amounts of stock.